Gillian McGovern, Editor

A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.

Marissa Reigelman of US Pharmacopeia explains how single-country dependence on key starting materials, combined with low prices, has kept 5 critical injectable drugs in shortage for more than a decade.

Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.

The investigational once-weekly dual GLP-1/GIP receptor agonist, engineered with signaling bias at both receptors, met both primary end points at 48 weeks.

A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.

Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.

This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.

The approval is supported by data from the phase 3 FINE-ONE clinical trial.

As centanafadine awaits DEA scheduling, Megan Maroney, PharmD, BCPP, FAAPP, and Danielle Stutzman, PharmD, BCPP, unpack what its modest efficacy data, favorable interaction profile, and pediatric dosing considerations mean for real-world ADHD prescribing.

Maroney and her guest, Danielle Stutzman, PharmD, BCPP, break down efficacy data and potential advantages of centanafadine, the newly approved triple reuptake inhibitor for ADHD.

A 5-level model for classifying AI-enabled pharmacy systems may help health systems advance to new levels of pharmacy autonomy.

This episode covers the importance of considering vaccine timing, selection, and hesitancy in patients on immunomodulating and immunosuppressive therapies, along with emerging data linking several vaccines to reduced dementia risk.

Melissa Seifert, PharmD, of UPMC Health Plan, explains how managed care pharmacists guide DMT selection and address adherence barriers in patients with MS.

A clinical pharmacy specialist at UPMC Health Plan discusses how pharmacists help select disease-modifying therapies, address adherence barriers, and coordinate whole-person care for those with MS.

The podcast will cover relevant areas in psychiatry, new literature and clinical data, new drugs, and other topics that are coming down the pipeline.

In this new show, host Megan Maroney, PharmD, BCPP, FAAPP, will examine therapies, trends, and clinical decisions shaping care for psychiatric conditions.

The approval is supported by clinical data from 2 studies.

The therapy is administered via an intratumoral injection every 2 weeks for 8 consecutive doses.

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses how pharmacists can layer mediator-symptom management with cytoreductive or targeted therapy in systemic mastocytosis (SM) and interdisciplinary communication.

The approval clears the way for a new vaccine option for older adults ahead of the 2026-2027 flu season.

Guest Jenelle Montgomery, PharmD, BCACP, CPP, joins Erica Marini to review key updates from the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.

Although the FDA committee's vote does not change what is currently legally available, it signals where the regulatory landscape is heading in the future.

Agitation associated with Alzheimer disease carries clinical challenges, and Auvelity's approval can reshape treatment selection, safety monitoring, and the pharmacist's role.

Erica Marini, PharmD, MS, BCPS; and Millad Sobhanian, PharmD, BCPS, unpack Auvelity's approval, efficacy data, and safety profile for treating agitation in Alzheimer disease.

Hackensack Meridian Health uses a multifaceted approach to diversion auditing and DEA/state reporting requirements, and is beginning to integrate artificial Intelligence (AI) to shift surveillance from a reactive to a proactive process.

Deepika Nayyar outlines how HMH built a multidisciplinary drug diversion prevention program and shares the core elements any institution needs to detect and respond to diversion effectively.

The review combines mechanistic and real-world evidence to guide health care professionals through different scenarios in the MS treatment space.

The autoinjector provides an accessible, at-home option for patients with chronic kidney disease or heart failure who need treatment for fluid buildup.

As 2026 wildfire smoke from Canada blankets the US, pharmacists can facilitate early refills, counsel on protective measures, and help patients understand when worsening symptoms require emergency care.

Erica Marini, PharmD, MS, BCPS, the host of "Mind the Meds," discusses the show's format, guest conversations, and upcoming episodes covering CAR T therapy and a Consortium of Multiple Sclerosis Centers Annual Meeting roundup.